Abstract:Chao Zhang, 1 Mengnan Han, 1 Fanghua Zhang, 1 Xueli Yang, 1 Jie Du, 1 Honglei Zhang, 1 Wei Li, 1 Shengxi Chen 2 1 College of Chemistry and Environmental Science, Key Laboratory of Chemical Biology of Hebei Province, Laboratory of Medicinal Chemistry and Molecular Diagnosis of the Ministry of Education, Hebei University, Baoding 071002, People's Republic of China; 2 Biodesign Center for BioEnergetics, Arizona State University, Tempe, AZ 85287, USA Correspondence: Honglei Zhang; Wei Li College of Chemistry and Environmental Science, Key Laboratory of Chemical Biology of Hebei Province, Laboratory of Medicinal Chemistry and Molecular Diagnosis of the Ministry of Education, Hebei University, Baoding 071002, People's Republic of China Tel/Fax +86 312 592 9009 Email zhanghonglei@hbu.edu.cn; liweihebeilab@163.com Background: Chemotherapy, as an adjuvant treatment strategy for HER2-positive breast cancer, can effectively improve clinical symptoms and overcome the drug resistance of therapeutic monoclonal antibodies. Nucleoside analogues are a class of traditional chemotherapeutic drugs that are widely applied in adjuvant therapy. However, there are many critical issues that limit their clinical efficiency, including poor selectivity and stability, severe side effects and suboptimal therapeutic efficacy. Hence, this work aims to develop a new DNA nanocarrier for targeted drug delivery to solve the above problems. Methods: Four 41-mer DNA strands were synthesized and 10 FUdR molecules were attached to 5ʹ end of each DNA strand by DNA solid-phase synthesis. An affibody molecule was connected to the end of polymeric FUdR through a linker in one of the four strands. The affibody-FUdR-tetrahedral DNA nanostructures (affi-F/TDNs) were self-assembled through four DNA strands, in which one vertex was connected to an affibody at the end of a polymeric FUdR tail and three vertices were only polymeric FUdR tails. In vitro cellular uptake of affi-F/TDNs was examined visually with confocal fluorescence microscopy and flow cytometry, and the cytotoxicity of affi-F/TDNs against cancer cells was investigated with MTT assay. Cell apoptosis was detected by Annexin V-FITC/PI double staining method. Using NOD/SCID (Mus Musculus) mice model, the targeted killing efficacy of affi-F/TDNs was also evaluated. Results: The drug-loading of FUdR in affi-TDNs was 19.6% in mole ratio. The in vitro results showed that affi-F/TDNs had high selectivity and inhibition (81.2%) for breast cancer BT474 cells overexpressing HER2 and low toxicity in MCF-7 cells with low HER2 expression. During the in vivo application, affi-F/TDNs displayed good stability in the blood circulation, achieved specific accumulation in tumor region and the best antitumor efficacy (inhibition ratio of 58.1%), and showed excellent biocompatibility. Conclusions: The affibody-DNA tetrahedrons, as a simple and effective active targeting delivery nanocarrier, provided a new avenue for the transport of nucleoside antitumor drugs. Keywords: 5-fluorodeoxyuridine, targeting therapy, her2, breast cancer, affibody, DNA nanoparticle

Bifunctional and Unusual Amino Acid β- or γ-Ester Prodrugs of Nucleoside Analogues for Improved Affinity to ATB 0,+ and Enhanced Metabolic Stability: An Application to Floxuridine

Design, Synthesis, and Evaluation of Doxifluridine Derivatives as Nitroreductase-Responsive Anticancer Prodrugs

Synthesis and Activity Evaluation of 3′‐floxuridinyl 4‐[3‐(3, 5‐di‐t‐butyl‐4‐methoxyphenyl)‐3‐oxo‐propenyl]benzoate: in Vitro and in Vivo As a Potential Dual‐acting Antitumor Prodrug

Optimized 5-Fluorouridine Prodrug for Co-Loading with Doxorubicin in Clinically Relevant Liposomes

Floxuridine Homomeric Oligonucleotides "hitchhike" with Albumin in Situ for Cancer Chemotherapy.

Discovery of an Orally Active and Liver-Targeted Prodrug of 5-Fluoro-2 '-Deoxyuridine for the Treatment of Hepatocellular Carcinoma

Novel ProTide Prodrugs of 5-Fluoro-2′-deoxyuridine for the Treatment of Liver Cancer

[Preparation of Floxuridine Loaded Polycation and Its Antitumor Activity].

Surface decoration of PLGA nanoparticles enables efficient transport of floxuridine oligomers into mammalian cells

Preparation of floxuridine diacetate solid lipid nanoparticles

Integrating Theory with Experimental Studies on the Directed Assembly of Phenforminium 5-Fluorouracilate Toward Enhanced in Vitro/Vivo Properties and Synergistic Antitumor Efficacy

Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators

Influence of bromoethyl group on biological activity of 5-fluorouracil prodrug: Insights from X-ray crystallography and molecular docking

Design, Synthesis, and Activity Evaluation of a New 5-Fluorouracil Prodrug Containing an Asn-Gly-Arg(NO2)COOCH3 Tripeptide

Multiple-grade prodrugs of 5-flulorouracil:synthesis and anti-tumor activities in mice

Esterase-Responsive Floxuridine-Tethered Multifunctional Nanoparticles for Targeted Cancer Therapy

Enhancing Antitumor Efficacy of Nucleoside Analog 5-Fluorodeoxyuridine on HER2-Overexpressing Breast Cancer by Affibody-Engineered DNA Nanoparticle

Two-step Synthesis of Structure-Diverse D-Galactose Conjugates and Polymeric Prodrugs of Floxuridine Via Controllable Regioselective Enzymatic Acylation of 3′- or 5′-OH Group of Floxuridine

Selective Bone Targeting 5-Fluorouracil Prodrugs: Synthesis and Preliminary Biological Evaluation

Metforminium 5-Fluorouracilate: the First Codrug Molecular Salt of 5-Fluorouracil Demonstrating Perfected in Vitro/vivo Characteristics and Synergic Antitumor Effects

Synthesis of F16 conjugated with 5-fluorouracil and biophysical investigation of its interaction with bovine serum albumin by a spectroscopic and molecular modeling approach.